GFBioRetrieve

GlycoForm is using its expertise in sugar chemistry to improve targeting and membrane transfer of molecules. Many candidate drugs fail because they lack the ability to cross into various compartments such as the brain. The addition of sugars can facilitate membrane transfer thus promoting the penetration of drugs across, for example, the blood-brain barrier.

GLY205 uses advanced knowledge of glycochemistry and conjugation to enhance the transport of molecules into the brain.

GFBioBetters

GlycoForm's homogeneous Novel Synthetic Glycotherapeutics will give optimised activity for best in class performance, GFBioBetters.

Glycoproteins, for example, occur naturally and 70% of all proteins in humans are glycosylated. Some of the most effective and life changing medications for patients are derived from human glycoproteins, from erythropoietin for the management of anaemia in renal disease and cancer patients through to monoclonal antibodies which destroy cancer cells.

The development of these important drugs has been difficult because they are glycosylated. Sugars are added by an enzymatic process which produces a mix of products known as glycoforms, with the same peptide backbone but with different sugars attached. Because all current protein expression methods produce mixtures of glycoforms, the biggest challenge has been to understand the structural activity relationships (SAR) of all these different glycoforms and the effect that each sugar type has on activity.

GlycoForm's technology enables true glycosylation pattern based SAR by using chemistry to construct pure sugars and then ligate these to proteins or other molecules in a very accurate and consistent manner. GlycoForm's approach also allows the rapid evaluation of natural and non-natural sites for glycosylation in the same way others have looked at pegylation or amino acid sequence changes to produce enhanced effects.

GlycoForm's chemistry-enabled, site-directed conjugation approach allows for the use of any expression system to derive a starting protein.

GLY202 is a single glycoform of a haematopoietic hormone with improved pharmacokinetic characteristics.

GFBioTherapeutics

GlycoForm is creating new molecules by utilising unique conjugation technologies and expertise in glycochemistry to create candidate drugs to fight serious diseases.

The first in this series is GLY515n, a neuroprotective biological, which has shown activity in models for stroke and post stroke haemorrhagic transformations.

Second in this series, GLY302 is an immunomodulator to combat a range of infections including Multi-Drug Resistant and Extensively Drug Resistant Tuberculosis.